Amica Mutual Insurance Co. Has $4.23 Million Stake in Zoetis Inc. $ZTS

Amica Mutual Insurance Co. grew its position in Zoetis Inc. (NYSE:ZTS) by 33.7% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 28,906 shares of the company’s stock after buying an additional 7,293 shares during the quarter. Amica Mutual Insurance Co.’s holdings in Zoetis were worth $4,229,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Halbert Hargrove Global Advisors LLC lifted its stake in Zoetis by 496.6% during the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock worth $25,000 after purchasing an additional 144 shares during the last quarter. NewSquare Capital LLC increased its stake in shares of Zoetis by 69.1% in the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. Financial Consulate Inc. acquired a new position in shares of Zoetis during the 3rd quarter worth $39,000. SJS Investment Consulting Inc. boosted its stake in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock valued at $40,000 after buying an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new stake in Zoetis in the third quarter valued at about $42,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Trading Up 0.8%

Shares of ZTS stock opened at $126.64 on Monday. Zoetis Inc. has a 1-year low of $115.25 and a 1-year high of $177.00. The company has a current ratio of 3.03, a quick ratio of 1.94 and a debt-to-equity ratio of 2.71. The stock has a market cap of $53.46 billion, a price-to-earnings ratio of 21.04, a PEG ratio of 2.12 and a beta of 0.96. The stock has a 50-day moving average of $124.42 and a 200-day moving average of $135.35.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The business had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, equities research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be paid a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio is currently 35.22%.

Key Zoetis News

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis beat Q4 EPS and revenue estimates, showing underlying margin resilience and international strength. Zoetis Surpasses Q4 Expectations, Predicts Strong 2026 Despite Growth Concerns
• Positive Sentiment: Company gave FY2026 guidance above Street expectations (EPS 7.00–7.10; revenue $9.8–10.0B), supporting a constructive forward earnings view. Zoetis forecasts strong 2026 profit, revenue on steady pet‑medicine demand
• Positive Sentiment: Analysts and outlets note the stock rose on the beat + upbeat guidance, driven by companion-animal demand and international growth offsetting U.S. weakness. Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates
• Positive Sentiment: Bank of America raised its price target from $135 to $140 (maintaining a “neutral” rating), signalling modest upside in analyst models. Benzinga
• Neutral Sentiment: Full earnings call transcript, slide deck and detailed metrics are available for investors who want line-item transparency on unit trends and product performance. Zoetis (ZTS) Q4 2025 Earnings Call Transcript
• Negative Sentiment: Several analysts flagged pressure in key business segments and questioned the durability of prior growth drivers, which could weigh on medium-term top-line momentum. Analysts Question Zoetis’ Pathway To Growth As Key Segments Slide
• Negative Sentiment: Coverage and commentary suggest investors remain wary of U.S. demand softness and competitive pressures despite the beat; headlines note the stock “slipped” on those outlook concerns. Zoetis slips as outlook shows pressure on topline growth
• Negative Sentiment: Commentary emphasizing why the stock is “in the doghouse” despite the beat points to market skepticism over sustainability of growth. Zoetis stock is in the doghouse despite its quarterly beat; here’s why

Analysts Set New Price Targets

Several brokerages recently commented on ZTS. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a report on Friday, January 23rd. Morgan Stanley set a $160.00 price target on Zoetis in a research note on Thursday, December 18th. Barclays assumed coverage on Zoetis in a report on Monday, December 8th. They set an “equal weight” rating and a $136.00 price target on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $160.00 price objective on shares of Zoetis in a report on Wednesday, December 3rd. Five research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $152.91.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.